3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Ovarian Neoplasms
7
Neoplasms
4
Endometrial Neoplasms
4
Breast Neoplasms
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoma
1
Liver Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Colonic Neoplasms
1
Interventions
Trastuzumab
3
Docetaxel
3
Biopsy
3
trastuzumab deruxtecan
2
pembrolizumab
2
Vorinostat
2
Taxes
2
SS1(dsFv)PE38
2
Polymerase Chain Reaction
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
Immunohistochemistry
2
Gene Expression Profiling
2
Flow Cytometry
2
zanidatamab
1
tipifarnib
1
tanespimycin
1
spartalizumab
1
sargramostim
1
pertuzumab
1
oncogene protein E7, Human papillomavirus type 16
1
neratinib
1
entrectinib
1
entinostat
1
ceralasertib
1
alectinib
1
aldesleukin
1
Specimen Handling
1
Ritonavir
1
Radiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
pertuzumab
×
Gynecologic
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled